Carbetocin Outperforms Oxytocin in Preventing Postpartum Hemorrhage After Vaginal Delivery

Postpartum Hemorrhage (PPH), defined as excessive bleeding after childbirth, remains a leading cause of maternal mortality worldwide, with uterine atony (failure of the uterus to contract) being the most common cause. Oxytocin is the standard prophylactic agent, but its efficacy can be limited in high-risk cases. This Phase 3 study aimed to determine if carbetocin, a longer-acting oxytocin analog, offers superior prevention of PPH compared to oxytocin in women with multiple risk factors for atonic PPH after vaginal delivery.

The study found a significant difference in the incidence of PPH between the two groups. Women receiving Carbetocin experienced a PPH rate of 5% (5 out of 100 women), compared to 15% (15 out of 100 women) in the Oxytocin group, representing a 66% reduction in PPH incidence (p<0.01). The average blood loss was 350 mL in the Carbetocin group versus 500 mL in the Oxytocin group (p<0.001), a 30% decrease. The most important finding was that Carbetocin significantly reduced the need for additional uterotonic agents by 43% compared to Oxytocin (p=0.005), indicating superior uterine contractility and less intervention. Furthermore, the duration of uterine contraction was sustained for 60 minutes in the Carbetocin group compared to 30 minutes in the Oxytocin group (p<0.001). No significant differences in adverse events were reported between the groups.